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ABSTRACT  
Transfer RNAs (tRNAs) are among the most heavily modified RNA species. Posttranscriptional 
tRNA modifications (ptRMs) play fundamental roles in modulating tRNA structure and function, 
and are being increasingly linked to human physiology and disease. Detection of ptRMs is often 
challenging, expensive and laborious. Restriction Fragment Length Polymorphism (RFLP) 
analyses study the patterns of DNA cleavage after restriction enzyme treatment; and have been 
used for the qualitative detection of modified bases on messenger RNAs. It is known that some 
ptRMs induce specific and reproducible base ‘mutations’ when tRNAs are reverse transcribed. For 
example, inosine, which derives from the deamination of adenosine, is detected as a guanosine 
when an inosine-containing tRNA is reverse transcribed, PCR-amplified and sequenced. ptRM-
dependent base changes on RT-PCR amplicons generated as a consequence of the reverse 
transcription reaction might create or abolish endonuclease restriction sites. The suitability of 
RFLP for the detection and/or quantification of ptRMs has not been studied thus far. Here we show 
that different ptRMs can be detected at specific sites of different tRNA types by RFLP. For the 
examples studied we show that this approach is able to reliably estimate the modification status of 
the sample, a feature that can be useful in the study of the regulatory role of tRNA modifications 





Transfer RNAs (tRNAs) are among the most heavily modified RNA species. Posttranscriptional 
modifications on tRNAs (ptRMs) may act as identity determinants for aminoacylation (e.g. 
posttranscriptional 5’-end guanosine addition on tRNAHis is essential for tRNA charging); they 
can affect codon decoding by expanding or restricting codon recognition; or contribute to tRNA 
structure and stability 1. In recent years ptRMs have become a strong focus of research, as 
mounting evidence points to roles for tRNA modifications in human pathologies such as cancer 
(e.g. 5-methylcytosine), diabetes (e.g. 2-methylthio-N6-threonylcarbamoyladenosine), 
neurological disorders (e.g. 5-methoxycarbonylmethyl-2-thiouridine), and mitochondrial-linked 
diseases (e.g. 5-taurinomethyluridine modifications on mitochondrial tRNAs), among others 2, 3. 
Unfortunately, the complex set of potential tRNA modifications makes their identification in any 
given tRNA extremely challenging. 
Available methods for the analysis of posttranscriptional RNA modification include: i) 
radiolabeling of RNA species followed by selective RNA digestion with specific RNases, and 
analysis of migration patterns by 2D-thin-layer chromatography 4; ii) the use of liquid 
chromatography coupled to mass spectrometry (LC-MS/MS) 5, 6; and iii) methods that involve the 
reverse transcription (RT) of RNAs 7. Additional methods have also been developed to study 
specific modifications such as the PHA6 assay in which isopentyl-N6-A37 can be detected based 
on the differential hybridization of an oligonucleotide against the anticodon loop of tRNAs 
carrying the modification 8; or the acryloylaminophenylboronic (APB) acid-based boronic affinity 
electrophoresis to detect queuosine modifications on tRNAs 9. 
Methods based on radiolabeling or mass spectrometry are usually laborious, low-throughput, 
and require specialized and expensive laboratory equipment and facilities. These methods may not 
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be easily applied to study ptRMs on specific tRNA residues, or to monitor physiological levels of 
endogenous ptRMs in vivo. In addition, RNA samples need to homogeneous, in some cases large 
amounts of starting material is required, and a specific expertise on experimental optimization and 
data interpretation is often necessary. Therefore, there is still a need for developing novel 
techniques for ptRM detection that would overcome some of these limitations.  
During RT, modified RNA bases may be either read by the reverse transcriptase as if 
unmodified, as a different base (resulting in a change in the resulting DNA sequence), or may 
block the advance of the reverse transcriptase causing an arrest in the transcript. These possible 
outcomes of the RT reaction are dependent on the nature of the RNA modification 7. Restriction 
Fragment Length Polymorphism (RFLP) is a technique that studies the patterns of DNA cleavage 
after restriction enzyme treatments 10. It has been widely used in the past as a medium- to high-
throughput technique to detect genetic polymorphisms, define DNA marker loci, perform genome 
mapping or gene tagging, and to construct genomic linkage relationships in human pedigrees 11. 
More recently, RFLP has been used to detect editing events on messenger RNAs such as 
adenosine-to-inosine (A-to-G mutation on the PCR product) and cytidine-to-uridine (C-to-T 
mutation on the PCR product) modifications 12-14; confirming that cDNA mutations caused by the 
reverse transcriptase can generate or abolish endonuclease restriction sites on PCR amplicons. 
  
DEVELOPMENT OF THE METHOD 
We envisaged that RFLP could be used to study ptRMs (Figure 1). Analyses of small-RNAseq 
data in search for mutated sites that are distinguishable from simple base-calling errors have 
proven useful to map several different ptRMs at genomic scale 15-18; suggesting that several ptRMs 
induce the incorporation of alternative nucleotides in the generated cDNA when the reverse 
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transcriptase reads a modified tRNA. In the past, we validated these findings by using small-
RNAseq to monitor the levels of inosine modifications on tRNAs in human cell lines 19.  
 
 
Figure 1. Posttranscriptional tRNA modifications discussed in this manuscript. Inosine, 1-
Methylinosine and 1-Methyladenosine nucleosides are derived from Adenosine. 2’-O-
Methylguanosine, 7-Methylguanosine and N2-Methylguanosine are derived from Guanosine. 
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Pseudouridine and Dihydrouridine are derived from Uridine. 5-Methylcytidine is derived from 
Cytidine.   
 
In this context, RFLP could be beneficial because, by avoiding the need of performing RNA 
sequencing, it would allow detection of inosine and other ptRMs in standard laboratory facilities, 
rapidly, and in a cost-effective manner. The RFLP method to detect ptRMs that we present here 
has four simple steps: RT, PCR amplification with specific primers, incubation of the PCR product 
with a specific restriction enzyme, and detection of the cleavage patterns by standard gel 
electrophoresis (Figure 2). Here, we have applied this method to study different ptRMs in different 
tRNA types, using in vitro and in vivo tRNA samples. We additionally show direct applications of 
the method to study, for example, the activity of a tRNA modification enzyme in vitro, or to 
monitor the levels of ptRMs in vivo. We believe that this method offers a new and useful approach 




Figure 2. Schematic representation of the RFLP method for ptRM detection. Detection of inosine 
at the first anticodon position (position 34; I34) on tRNAs is shown as an example. During RT, 
the reverse transcriptase reads I34 as a G and incorporates a C on the cDNA strand. Therefore, 
after PCR amplification, the original I34 position is read as a G34. The obtained amplicon is then 
digested with a specific restriction enzyme that would recognize and cleave the target in a 
modified/unmodified residue-dependent manner. The products of digestion are then resolved by 
gel electrophoresis and the proportion of cleaved:uncleaved amplicon can be quantified to estimate 
the levels of modified tRNA.   
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VALIDATION OF THE METHOD 
Detection of inosine from in vitro tRNA samples. As a proof of concept, we first decided to 
apply the RFLP method to in vitro tRNA samples, and to focus on inosine detection (Figure 1). 
Inosine is present at the first position of the anticodon (position 34; ‘wobble’ position) of bacterial 
tRNAArgACG and 7-8 eukaryotic tRNAs. It is the result of a deamination reaction of adenosine, 
catalyzed in eukaryotes by the heterodimeric adenosine deaminase acting on tRNAs (hetADAT). 
Inosine is one of the few essential ptRMs described, as it is required to expand the number of 
codons that genetically encoded A34-containing tRNAs can recognise 20. 
In vitro transcribed human tRNAAlaAGC, a natural substrate of hetADAT, was incubated with 
purified human hetADAT. The reaction product was then reverse transcribed and amplified by 
PCR. Deamination was confirmed by sequencing the PCR amplicon, a commonly used strategy 19, 
21-25 (Figure 3A). As expected, A34 was detected on the in vitro transcribed tRNA (Figure 3A 
upper panel), but was fully converted to I34 (detected as G34) upon incubation with hetADAT 
(Figure 3A bottom panel). An in silico search for restriction enzymes revealed that Bpu1102I 
(BlpI) would recognize and cleave a PCR amplicon derived from unmodified tRNAAlaAGC (A34) 
but would not cleave the tRNAAlaIGC-derived counterpart (G34) (Figure 3B). Indeed, upon 
incubation with Bpu1102l, only the PCR amplicon derived from the unmodified tRNA was cleaved 
(Figure 3C). Importantly, no cleavage was observed for the modified tRNA, consistent with the 
100% modification status of the in vitro transcribed tRNA upon incubation with hetADAT 
observed by sequencing (Figure 3A). Similar results were obtained for in vitro transcribed 
tRNAThrAGU (Supporting Information Figure S1 A-C). This set of experiments shows that results 
obtained with the RFLP method are in agreement with those obtained by sequencing.  
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Figure 3. Evaluation of in vitro deamination by human hetADAT on in vitro transcribed 
tRNAAlaAGC. (A) Sequencing spectrum for in vitro transcribed tRNA
Ala
AGC incubated or not with 
human hetADAT. I34 is detected as G34. (B) Schematic representation of the recognition site for 
Bpu1102l for amplicons derived from unmodified (upper panel) or modified (lower panel) tRNA. 
The arrow indicates the modification site (Position 34 on the tRNA). Bpu1102l will cleave the 
amplicon only when it is derived from unmodified tRNAAlaAGC. (C) Evaluation of in vitro 
deamination by human hetADAT on in vitro transcribed tRNAAlaAGC using the RFLP method. 
After cDNA synthesis, PCR amplification and digestion with Bpu1102l, samples were resolved in 
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a 2% agarose gel. As expected, the full length amplicon is fully cleaved only when A34 is not 
modified. 
 
To further characterize this method, we tested its sensitivity towards I34 detection and its 
potential to be used in a semi-quantitative manner. Fully modified- and fully unmodified-in vitro 
transcribed tRNAAlaAGC were mixed at known proportions. The levels of I34 modification were 
next evaluated by RFLP and the observed gel bands were quantified. Figure 4A shows a 
representative gel obtained for this type of experiment. Gel quantification of three independent 
replicates revealed a linear correlation (R2=0.99) between the expected and the observed levels of 
I34 (Figure 4B) suggesting that the method can be semi-quantitative. Importantly, the method 
proved to be sensitive enough to reliably detect low levels of modification (expected: 1% I34; 
observed: 2.80 ± 1.05 % I34) (Figure 4B). 
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Figure 4. Evaluation of the sensitivity and accuracy of the RFLP method for ptRM detection. Fully 
modified- (I34) and fully unmodified- (A34) in vitro transcribed tRNAAlaAGC were mixed at the 
indicated proportions. The RNA mix was then reverse transcribed, PCR amplified, digested with 
Bpu1102I, and ran in a 2% agarose gel. The cleavage pattern was quantified using ImageJ. (A) A 
representative gel showing the obtained quantification results. Band quantification was normalized 
to total lane intensity (uncleaved + cleaved band). (B) Plot of the estimated levels of I34 on in vitro 
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transcribed tRNAAla by RFLP (continuous regression line: y=1.084x; R2=0.99) against the 
theoretically expected levels of modification (dotted regression line: y=x; R2=1). Mean and 
standard deviations are shown for three independent replicates. Curve fitting was performed 
following a linear regression model.   
 
We next applied the RFLP method to monitor the effect of different reaction conditions on 
hetADAT activity by varying the pH and magnesium (Mg2+) concentrations of the reaction buffer. 
As shown in Figure 5, optimal deamination of tRNAAlaAGC was achieved at pH 8.0 and 1 mM 
Mg2+. These results suggest that hetADAT activity in vitro is sensitive to pH and Mg2+ 
concentrations; and illustrate the potential use of the method in reaction optimization.  
 
Figure 5. Evaluation of in vitro deamination efficiency by human hetADAT on in vitro transcribed 
tRNAAlaAGC. Different reaction conditions (variable pH and Mg
2+) were evaluated using the RFLP 
method. Samples were resolved in a 2% agarose gel. Band quantification was normalized to total 
lane intensity (uncleaved + cleaved band). Optimal reaction conditions were observed at pH 8.0 
and 1 mM Mg2+. 
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Detection of inosine from in vivo tRNA samples. We then applied the RFLP method to the 
detection of ptRMs in tRNAs from in vivo samples. HeLa cells expressing a short hairpin RNA 
(shRNA) against human ADAT2, the catalytic subunit of hetADAT, were generated. We have 
previously shown that knockdown (KD) of ADAT2 in a human cell line causes partial 
downregulation of I34 levels on all 8 tRNA substrates of hetADAT 19. Using quantitative real time 
PCR, ADAT2 was found downregulated in shADAT2 cell lines as compared to cells expressing a 
non-target control shRNA (shCV) (Figure 6A). The RFLP method for ptRM detection was then 
used to evaluate the levels of I34 on endogenous tRNAAlaAGC in these cell lines. As previously 
shown (Figure 3), the amplicon derived from tRNAAlaIGC should not be cleaved by Bpu1102I. As 
expected, a higher degree of amplicon cleavage was observed in shADAT2 cells, consistent with 
lower levels of I34 for this tRNA (Figure 6B). Similar results were obtained for endogenous 
tRNAThrAGU, another natural substrate of hetADAT (Supporting Information Figure S1D). 
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Figure 6. Evaluation of in vivo I34 levels on tRNAAlaAGC in HeLa cells. (A) Quantitative Real-
Time PCR for ADAT2 in HeLa cells expressing a control shRNA (shCV) or an ADAT2 shRNA 
(shADAT2). ADAT2 levels are expressed relative to GAPDH. Statistical significance was 
obtained with a t-test (n = 3; **: p-val < 0.01). (B) Evaluation of in vivo I34 levels on tRNAAlaAGC 
in HeLa shCV and HeLa shADAT2 cells using the RFLP method. A representative experiment is 
shown. Samples were resolved in a 15% polyacrylamide gel. RT (-): no reverse transcriptase in 
RT reaction; H2O RT (+): reverse transcription using water as template (no RNA template); H2O 
PCR: PCR reaction using water as template (no cDNA template). Band quantification normalized 
to total lane intensity (uncleaved + cleaved bands) is shown. Quantification of ‘Cleaved bands’ 
corresponds to the sum of both 3’ and 5’ amplicon halves. Statistical significance was obtained 
with a t-test (***: p-val < 0.001) and corresponds to the comparison between the remaining 
uncleaved band after Bpu1102I digestion for HeLa shCV and HeLa shADAT2 cells on three 
independent replicates (n = 3). 
 
tRNAs genetically encoded with A34 are known to be almost fully modified to I34 when fully 
matured 20, 26. It was therefore surprising to observe a significant amount of amplicon cleavage for 
tRNAAlaAGC and tRNA
Thr
AGU in HeLa shCV cells (Figure 6B and Supporting Information 
Figure S1D). We sequenced the obtained amplicons for these samples and confirmed that A34 
was present on both tRNAs (Supporting Information Figure S2). After ruling out possible 
contamination of the PCR reaction with genomic DNA (Figure 6B) we concluded that part of the 
obtained amplicons were derived from unmodified precursor tRNA species. It is well known that 
RT of fully matured tRNAs is challenging and that in complex RNA samples, there is a bias 
towards reverse transcribing precursor tRNAs over mature tRNAs 19, 27-29. Despite amplifying 
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precursor tRNAs, our data shows a trend for lower levels of I34 in RNA samples derived from 
ADAT2 KD cells. This demonstrates that the RFLP method can be used for the detection and 
relative semi-quantification of ptRMs in vivo (see Discussion section). To facilitate the use of the 
RFLP method to detect I34 levels on tRNAs, we have compiled the tRNA substrates that could 
potentially be studied with this technique and the required restriction enzymes that would 
recognize either the A34 or I34 version of the PCR amplicon, for all model organisms where I34 
has been studied (Table 1) 19, 21-25. 
 
Table 1. tRNAANN substrates of A34-to-I34 editing in model organisms and restriction enzymes 
that could be used to detect such modification using the RFLP method. 
tRNA undergoing 
A34-to-I34 editing 
Restriction enzyme for amplicon cleavage# 
Unmodified 
(ANN RNA / ANN cDNA) 
Modified 
(INN RNA / GNN cDNA) 
Escherichia coli K12 
Arginine ACG - TseI, Fnu4HI 
Homo sapiens 
Alanine AGC Bpu1102I - 
Arginine ACG - AciI 
Isoleucine AAU - - 
Leucine AAG MseI - 
Proline AGG DdeI, Bpu10I - 
Serine AGA XspI - 
Threonine AGU XspI - 
Valine AAC - - 
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Arabidopsis thaliana 
Alanine AGC Bpu1102I - 
Arginine ACG AccI, Hpy166II - 
Isoleucine AAU - - 
Leucine AAG MseI - 
Proline AGG DdeI - 
Serine AGA XspI BsrI 
Threonine AGU - - 
Valine AAC - Hpy188I 
Trypanosoma brucei 
Alanine AGC Bpu1102I BglI 
Arginine ACG TspGWI AciI 
Isoleucine AAU - Hpy188I 
Leucine AAG MseI MnlI (2 cutter) 
Proline AGG Bsu36I, DdeI StyI 
Serine AGA XspI BsrI 
Threonine AGU XspI StyD4I, BstNI 
Valine AAC MseI - 
Saccharomyces cerevisiae 
Alanine AGC Bpu10I, DdeI BsaJI, StyI 
Arginine ACG - TseI, Fnu4HI, BbvI 
Isoleucine AAU - - 
Proline AGG Bpu10I, DdeI - 
Serine AGA - - 
Threonine AGU SpeI, XspI BsrI, TspRI 
Valine AAC MseI - 
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Schizosaccharomyces pombe 
Alanine AGC Bpu10I, DdeI BsaJI, StyI 
Arginine ACG - AciI (2 cutter) 
Isoleucine AAU - Hpy188I 
Leucine AAG MseI - 
Proline AGG DdeI - 
Serine AGA BfaI BsrI 
Threonine AGU BfaI StyD4I, BstNI 
Valine AAC MseI - 
# Only one isoschizomer is shown. 
 
Detection of other ptRMs from in vivo tRNA samples. We performed an in silico search for 
additional restriction sites in unmodified human tRNAAlaAGC sequences that may be useful for the 
detection of additional ptRMs. A restriction site for the enzyme SphI (GCATGC) was found in 
positions 35-40, a region that can incorporate 1-methylinosine at position 37 (m1I37), 
pseudouridine at position 38 (Ψ38) and 2’-O-methylguanosine at position 39 (Gm39) 30 (Figure 
1). We found that under conditions where the PCR amplicon derived from in vitro transcribed 
tRNAAlaAGC (unmodified tRNA) is fully cleaved, the amplicon obtained from in vivo tRNA
Ala
AGC 
is only partially cleaved (Figure 7A). This is consistent with at least one of the aforementioned 
modifications inducing a detectable ‘mutation’ on the PCR amplicon. Of note, m1I37 has been 
reported to induce such a mutation as detected by RNAseq 15, 19. To show the robustness of the 
method using in vivo tRNA samples, we performed three independent replicates for this 
experiment (Figure 7B). The results suggest that the RFLP method can detect other modifications 
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besides inosine, although in this particular case it is not possible to determine the exact nature of 
the modification(s) (see Discussion section).    
 
Figure 7. Evaluation of in vivo ptRMs on tRNAAlaAGC in HeLa cells using the RFLP method. (A) 
SphI recognizes a region of unmodified tRNAAlaAGC comprising positions 35-40 of the tRNA 
expected to be modified to m1I37, Ψ38, and Gm39. Samples were resolved in a 15% 
polyacrylamide gel. In vitro tRNAAlaAGC and the endogenous tRNA
Ala
AGC were amplified using 
different primers (see Supporting Information Table S1); hence the difference in their full length 
size. Expected sizes of the endogenous tRNAAlaAGC amplicon 5’- and 3’-halves are shown. Bands 
were quantified and normalized to total lane intensity (uncleaved + cleaved bands). Quantification 
of ‘Cleaved bands’ corresponds to the sum of both 3’ and 5’ amplicon halves. (B) Quantification 
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of three independent experiments as that shown in (A). Statistical significance was obtained with 
a t-test (n = 3; ***: p-val < 0.001).  
 
Lastly, we wanted to study RNA modifications on a different tRNA substrate. We chose 
tRNAVal, and used in vitro transcribed tRNAValAAC as unmodified tRNA control. We reverse 
transcribed and PCR amplified in vitro transcribed tRNAVal, and endogenous tRNAVal from HeLa 
cells, using the same primers. We sequenced the PCR amplicon obtained from the endogenous 
tRNA and found that two isoacceptors were being amplified: tRNAValAAC and tRNA
Val
CAC 
(Supporting Information Figure S3); this is expected as the sequences of these two isoacceptors 
are very similar to each other 31. Notably, at position 34 both C (from tRNAValCAC) and G were 
found. Given that there are no predicted tRNAValGAC genes in the human genome 
31, this result is 
consistent with A34 from tRNAValAAC being deaminated to I34 (detected as G34).  
We next searched for restriction enzymes that would recognize other regions of tRNAVal 
expected to be modified. We chose two enzymes: HpyCH4IV (ACGT) and AvalI (GGWCC), that 
target sites likely to contain N2-methylguanosine (m2G) and Ψ; and 7-methylguanosine (m7G), 
dihydrouridine (D) and 5-methylcytidine (m5C), respectively (Fig 8A). m2G has been reported to 
induce RT-dependent mutations as observed by RNAseq 17. As a negative control, we chose TaqαI 
(TCGA). This enzyme targets a site for 1-methyladenosine (m1A) and Ψ. Since m1A is known to 
cause a hard-stop on reverse transcription 28, 29, 32, 33 and Ψ is considered an RT-silent modification 
34 (i.e. it does not induce a hard-stop on the RT and the reverse transcriptase recognizes it as an 
unmodified U), the RFLP method should not be able to detect these modifications and therefore, 
a PCR amplicon derived from tRNAs modified in this region should be fully cleaved by the 
restriction enzyme. All three enzymes tested fully cleaved the PCR amplicon derived from the in 
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vitro (unmodified) tRNAVal. As expected, the PCR amplicon derived from endogenous tRNAVal 
was also fully cleaved by TaqαI. However, this amplicon was only partially cleaved by HpyCH4IV 
and AvalI, consistent with partial tRNA modification on these regions (Figure 8B and Figure 8C). 
 
Figure 8. Evaluation of in vivo ptRMs on tRNAVal in HeLa cells using the RFLP method. (A) 
tRNAVal sequence. Bold residues show the recognition site for the indicated restriction enzyme. 
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Underlined residues are those expected to be modified within the restriction site. Expected 
modifications are shown: m2G26 (N2-Methylguanosine at position 26), Ψ27 (Pseudouridine at 
position 27), m7G46 (7-Methylguanosine at position 46), D47 (Dihydrouridine at position 47), 
m5C48/49 (5-Methylcytidine at positions 48 and 49), Ψ55 (Pseudouridine at position 55), m1A58 
(1-Methyladenosine at position 58); see also Figure 1. (B) Restriction enzyme cleavage patterns 
observed for PCR amplicons derived from in vitro transcribed tRNAVal (in vitro transcribed) or 
endogenous tRNAVal (HeLa). Samples were resolved in a 15% polyacrylamide gel. Expected band 
sizes: full length 104 bp (arrow), HpyCH4IV 5’-half 45 bp and 3’-half 59 bp, AvalI 5’-half 66 bp 
and 3’-half 38 bp, Taqα1 5’-half 76 bp and 3’-half 28 bp. (C) Quantification of three independent 
experiments as that shown in (B). Bands were quantified and normalized to total lane intensity 
(uncleaved + cleaved bands). Quantification of ‘Cleaved bands’ corresponds to the sum of both 3’ 
and 5’ amplicon halves. Statistical significance was obtained with a t-test (n = 3; *: p-val < 0.05; 
ns: not statistically significant). 
 
DISCUSSION 
In recent years RNA modifications in tRNAs have emerged as a fundamental aspect of tRNA 
function and regulation, and highly relevant to human physiology 2, 3. Moreover, while in the past 
ptRMs were considered rather static, mounting evidence now suggests that they can be dynamic 5, 
6. This prompts for the development of new techniques to efficiently detect, quantify, and monitor 
ptRMs. The RFLP method for ptRM detection can semi-quantitatively detect ptRMs on specific 
tRNA bases, and in different tRNA species. The method involves four steps: cDNA synthesis, 
PCR amplification with specific primers, digestion of the obtained amplicon with restriction 
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endonucleases, and detection of cleavage patterns by gel electrophoresis (Figure 2). Altogether, 
results can be obtained in less than 10 hours (see Step-by-step method description section).  
We applied the RFLP method to evaluate the levels of ptRMs on in vitro transcribed tRNAs and 
on endogenous in vivo tRNA species. We show that, at least for I34 detection, the method can be 
used in a semi-quantitative manner, and has enough sensitivity to detect the modification even 
when it is present in only 1 % of the tRNA population (Figure 4). We monitored A34-to-I34 
editing by human hetADAT in vitro and under different reaction conditions using this approach, 
and showed that this method can be used to determine the optimal parameters for the deamination 
reaction (Figure 5). It is likely that the RFLP method could also be useful to perform kinetic (time 
course) assays of hetADAT activity in vitro. We are currently performing a full in vitro 
characterization of hetADAT activity and we are hoping to shed light into this matter in the near 
future.  
Two types of techniques are currently being used to detect ptRMs: LC-MS/MS and RNAseq. 
The principal advantages of RNAseq over LC-MS/MS methods, are the fact that small amounts of 
RNA are required, and that detected ptRMs can be directly assigned to the tRNA sequence 15-19, 27-
29. The major drawback of RNAseq is that it often results in the detection of partially modified 
precursor tRNAs, rather than fully mature tRNAs 19, 27.  
In our analysis of I34 modifications on endogenous tRNAs, sequences from unmodified 
precursor tRNAs were also detected (Figure 6B and Supporting Information Figure S2). 
However, we were able to show that RFLP can be used to detect a relative decrease of I34 
nucleotides in two tRNAs from HeLa cells when ADAT2 expression is silenced (Figure 6 and 
Supporting Information Figure S1D). The partial downregulation of I34 levels in ADAT2 KD 
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HeLa cells observed with the RFLP method was consistent with that reported in ADAT2 KD 
HEK293T cells using an RNAseq strategy 19.  
We also analyzed the potential of RFLP to detect other ptRMs in vivo. We intentionally focused 
on regions of tRNAs where several ptRMs might be present and have selected sites on tRNAAlaAGC 
and tRNAValAAC/CAC in order to study m
1I, Gm, D, m2G, m7G, and m5C. RFLP on all the studied 
sites of potential ptRMs demonstrated partial cleavage of the PCR amplicon (indicating the 
presence of a ptRM) (Figure 7 and Figure 8). Treatment of tRNAVal amplicons with HpyCH4IV 
revealed the presence of m2G26 and/or Ψ27 on in vivo tRNAs. Given that Ψ cannot be readily 
detected with the RFLP method (see above), our results indicate that RFLP is suitable to detect 
m2G26 modifications (Figure 8). This is in agreement with the report by Iida and colleagues of 
m2G sites located on the D-loop of tRNAs that are detected as C, U or A ‘mutations’ on PCR 
amplicons following deep sequencing 17.  
Similar to Ψ, both D and m5C modifications are considered RT silent ptRMs 35. D and m5C 
ptRMs are present in a region of tRNAVal that also contains m7G (m7G46, D47, m5C48, and m5C49 
respectively) 30, and is a potential restriction site for AvalI (Figure 8A). Given the silent nature of 
D and m5C, the observed partial cleavage of tRNAVal amplicons with AvalI (Figure 8B and Figure 
8C) suggests that RFLP can also detect the m7G46 modification on this tRNA.  
Finally, we also assessed the detection of m1I37, Ψ38 and Gm39 on tRNAAlaAGC by means of 
amplicon cleavage by SphI (Figure 7). We detected partial amplicon cleavage of in vivo 
tRNAAlaAGC consistent with ptRM detection on at least one of these residues. Gm39 is known to 
be an RT-silent ptRM 7, 35, therefore m1I37 is likely responsible for the observed partial cleavage 
of the PCR amplicon. We and others have previously shown that sequencing of m1I results mainly 
in A-to-T or A-to-G ‘mutations’ on PCR amplicons, and that such ‘mutations’ can be detected in 
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amplicons derived from precursor tRNAs 15, 19. Altogether, these results support the use of the 
RFLP method to detect, in vitro or in vivo, different ptRMs such as I, m2G, m7G and m1I in different 
tRNA species. 
As mentioned above, the RFLP method for ptRM detection has some limitations. First, it 
requires the reverse transcription and amplification of the tRNA of interest. This is a significant 
problem for amplifying mature tRNAs, that may contain other ptRMs incompatible with RT 
reactions 7. As discussed above, this may introduce a bias towards reverse transcribing partially 
modified precursor tRNAs over fully modified mature tRNAs. However, we believe that once the 
RT step is completed the PCR step of the RFLP method will not introduce additional biases (i.e. 
the obtained cDNA template contains standard DNA bases). Despite this limitation, we show that 
it is possible to assess the modification status of tRNAs when the ptRM is incorporated at the 
precursor tRNA level, as it is the case for I34 and m1I37 (Figure 6B, Supporting Information 
Figure S1D, and Figure 7) 19.  
However, we note that the detected levels of ptRM under these conditions do not quantitatively 
represent the physiological levels of ptRMs on fully mature tRNAs. For example, in Figure 6B 
and Supporting Information Figure S1D, control cells showed ~10% of I34 modification on 
substrates expected to be ~100% modified when fully matured. Therefore, the RFLP method can 
accurately quantify the levels of ptRMs on in vitro tRNA substrates (Figure 4); and it allows for 
a relative quantification with respect to control cells in in vivo samples. In the aforementioned 
example, shADAT2 cells show ~4 fold less I34 on tRNAAla and tRNAVal as compared to shCV 
cells.    
Obviously the RFLP method requires that the studied ptRM causes the incorporation of an 
alternative nucleotide on the reverse transcribed cDNA (e.g. Ψ could not be detected; Figure 8). 
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Here we have focused on four modifications that have this effect: m2G26, I34, m1I37 and m7G46. 
Other ptRMs that share this property, and might be detected by RFLP, are cytidine deaminations 
(C-to-T), 1-methylguanosine (m1G) (G-to-T or C), 3-methylcytosine (m3C) (C-to-T or A), N2-N2-
dimethylguanosine (m22G) (G-to-A or T), N4-acetylcytidine (ac
4C) (C-to-A), and N6-
threonylcarbamoyladenosine (t6A) (A-to-C) 15-17, 25, 26, 36.  
Some of these ptRMs have been reported to cause hard-stops on RT, so they may not be easily 
detected by RFLP; as in the case for m1A58 modification (Figure 8). However, it is important to 
note that the ptRM-mediated misincorporation of nucleotides during cDNA synthesis has been 
reported to be sequence context dependent 33, 36; therefore a comprehensive and systematic analysis 
of reverse transcriptase behavior when encountering ptRMs in a sequence context dependent 
manner is needed.  
Finally, RFLP is limited by the need of a restriction enzyme that will differentially recognize the 
region of interest where ptRMs induce a change of sequence in their transcripts. In general, we 
have found useful restriction enzymes for most of our targets of interest. As an example, Table 1 
gives an estimation of how frequently a restriction enzyme exists to identify A34-to-I34 conversion 
on tRNAs in different organisms. This limitation may be overcome with the advent of 
CRISPR/Cas9-based methods developed to facilitate the in vitro digestion of DNA at sites for 
which no endonuclease is available 37. 
Although RFLP is designed to evaluate the modification status of tRNA residues known (or 
suspected) to be modified (e.g. Figure 7 and Figure 8), it can also be used as an initial screening 
step to detect new modification sites. In this case, we would recommend using as many restriction 
enzymes as possible to ensure a significant tRNA sequence coverage. Additionally, the selected 
restriction enzyme should recognize the unmodified residue and, if full cleavage is not observed, 
 26 
the presence of a modification can be suspected, and other independent means (e.g. LC-MS/MS 
using the purified specific tRNA type of interest) may be used to characterize it. 
 
STEP-BY-STEP DESCRIPTION OF THE RFLP METHOD FOR ptRM DETECTION 
RNA was reverse transcribed with the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems; Part number: 4368814). RT of tRNA species was carried out using 100 ng in vitro 
transcribed tRNA or 2 µg total RNA as RT template in a final reaction volume of 20 µL. These 
amounts of starting material are significantly lower than what used for other methods. For 
example, an optimized LC-MS/MS method for ptRM detection has been recently reported in which 
12 µg of total tRNA pool or 2 µg of a single tRNA was required as starting material 38. For 
experiments depicted in Figure 4 fully modified- and fully unmodified-in vitro transcribed 
tRNAAlaAGC were mixed at the indicated proportions for a total amount of 100 ng RNA (e.g. 80 
(I34): 20 (A34) proportions corresponds to 80 ng of in vitro transcribed tRNAAlaIGC mixed with 20 
ng of in vitro transcribed tRNAAlaAGC, prior to RT reaction). 10 pmol of specific RT-primers 
(Supporting Information Table S1) were used for each tRNA species. RT-cycle: 10 min at 25 
ºC; 60 min at 37 ºC; 5 min at 85 ºC. Estimated time required for this protocol step: 1 hour 30 
minutes. 
3 µL total RNA-derived cDNA were used for a standard 50 µL PCR reaction. 10 µL in vitro 
transcribed tRNA-derived cDNA were used for a standard 100 µL PCR reaction. Forward and 
Reverse primers used for PCR amplification of each target are detailed in Supporting 
Information Table S1. PCR cycle: 5 min at 94 ºC (1x cycle); 30 sec at 94 ºC, 15 sec at target-
specific annealing temperature (Supporting Information Table S2), 15 sec at 72 ºC (35x cycles); 
5 min at 72 ºC (1x cycle). Estimated time required for this protocol step: 2 hours. 
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When required, PCR amplicons were purified using the NucleoSpin Gel and PCR Clean-up kit 
(Macherey-Nagel; Ref number: 740609.250) and were sequenced using their respective forward 
and reverse PCR primers as sequencing primers (GATC Biotech). PCR amplicons were digested 
with 5 U of the appropriate restriction enzyme in 1x recommended reaction buffer; following the 
manufacturer’s protocol, except that we extended the recommended incubation time for an 
additional 2 hours to ensure full cleavage of the target PCR amplicon. Enzymes used in this study 
were as follows: Bpu1102I (Thermo Scientific; Cat Number: ER0091); XspI and SphI 
(Takara/Clontech; Cat Number: 1095A and 1246A, respectively); HpyCH4IV, AvalI and Taqα1 
(New England Biolabs; Cat Number: R0619S, R0153S and R0149S, respectively). PCR amplicon 
digestions using HpyCH4IV, AvalI and Taqα1 were carried out with a total of 30 U of enzyme for 
4 hours, by adding 15 U of enzyme every 2 hours to the reaction. Estimated time required for this 
protocol step: between 3 hours and 6 hours depending on the restriction enzyme digestion 
conditions.  
Digested samples were then resolved in 2 % agarose gels or 15 % polyacrylamide gels (ran for 
1 hour at 120 V). Similar results were obtained when using either gel type (Supporting 
Information Figure S1C), but in some cases higher resolution may be achieved by PAGE. When 
required, gel bands were quantified using ImageJ. In our experience the full RFLP method for 
ptRM detection can be usually performed in less than 10 hours.  
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